Tylenol-maker Kenvue’s stock has lost a quarter of its value in 6 months as momentum grows for autism link despite repeated denials

Kenvue, the maker of Tylenol, has seen its stock plummet by 25% over the past six months amid rising concerns about a potential link between acetaminophen and autism. Despite Kenvue's strong denials of any connection and their expressed concern for the health risks to expecting mothers, the stock's decline reflects growing skepticism among investors. This situation is significant as it highlights the ongoing debate over the safety of common medications during pregnancy and the impact of public perception on pharmaceutical companies.